Clinical Trials

35 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT07432568 2026-02-25

A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

30 enrolled

Cholangiocarcinoma

NCT07405086 2026-02-12

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

160 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT05166239 2026-01-23

HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT

Phase 2 Completed

66 enrolled

Carcinoma, Hepatocellular

NCT07339488 2026-01-14

ILDR-03

43 enrolled

Esophageal Squamous Cell Carcinoma

NCT07279077 2025-12-26

MODIFI-L

38 enrolled

Colonic Neoplasms

NCT07282262 2025-12-15

An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

300 enrolled

Biliary Tract Neoplasms

NCT06154538 2025-11-28

Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer

170 enrolled

Locally Advanced Colorectal Carcinoma

NCT07230301 2025-11-17

Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions

20 enrolled

Pancreatic Cancer Metastatic

NCT07007182 2025-09-05

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

54 enrolled

Stomach Neoplasms

NCT07157306 2025-09-05

Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma

35 enrolled

Carcinoma, Hepatocellular

NCT07064668 2025-07-15

Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study

300 enrolled

Carcinoma, Hepatocellular

NCT07040098 2025-06-26

STELLARIII

228 enrolled

Locally Advanced Rectal Cancer (LARC)

NCT06957977 2025-05-06

A Randomized Controlled Study of Endoscopic Cryoablation Combined With PD-1 Inhibitor for Maintenance Therapy in Advanced Gastric Cancer

42 enrolled

Stomach Neoplasms

NCT06685887 2025-04-11

A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis

34 enrolled

Stomach Neoplasms

NCT06890624 2025-03-27

OPTICAL-3

138 enrolled

Colonic Neoplasms

NCT06835179 2025-02-19

SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.

28 enrolled

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT05491616 2025-02-13

SANO-3

77 enrolled

Esophageal Neoplasms

NCT04230759 2024-09-19

RADIANCE

180 enrolled

Anus Neoplasms

NCT06543836 2024-08-09

ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer

68 enrolled

Colorectal Neoplasms

NCT04715633 2024-07-09

PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer

53 enrolled

Colorectal Neoplasms

NCT06084897 2024-06-14

Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy

120 enrolled

Esophageal Neoplasms

NCT06342167 2024-06-11

Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma

57 enrolled

Locally Advanced Esophageal Squamous Cell Carcinoma

NCT03817736 2024-05-09

START-FIT

Phase 2 Completed

33 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06321081 2024-03-20

ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC

60 enrolled

Colorectal Neoplasms

NCT06304987 2024-03-19

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

50 enrolled

Locally Advanced Rectal Cancer

NCT06186609 2024-01-02

PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC

68 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT05450029 2023-09-26

SILAR

51 enrolled

Rectal Neoplasms

NCT05994456 2023-08-16

Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer

24 enrolled

Stomach Neoplasms

NCT05913661 2023-06-22

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

30 enrolled

Carcinoma, Digestive System Neoplasms, Cholangiocarcinoma

NCT05845268 2023-05-06

Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer

102 enrolled

Locally Advanced Rectal Cancer

NCT05048017 2023-03-29

Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma

20 enrolled

Carcinoma, Hepatocellular

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

441 enrolled

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT05163483 2023-03-06

Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer

87 enrolled

Esophageal Squamous Cell Carcinoma

NCT05509478 2022-09-10

LEADER-001

46 enrolled

Biliary Tract Neoplasms

NCT05371197 2022-05-12

Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer

26 enrolled

Turcot syndrome, Colorectal Neoplasms

NCT05007145 2021-12-21

REVO

92 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT04814043 2021-09-22

PLATIC

57 enrolled

Carcinoma, Hepatocellular

NCT05035381 2021-09-05

PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer

GastrointestinalOther solid neoplasm

10 enrolled

MSI-H Advanced Colorectal Cancer

NCT04814030 2021-04-23

AIPD-1

80 enrolled